Mike Mahoney, the chief executive officer of Boston Scientific Corporation (NYSE:BSX) recently disclosed his company’s strategy for ensuring strategic growth during an investment community meeting in New York on Tuesday.

The company hosted the meeting in New York and Mahoney talked about Boston Scientific’s long-term strategy including how the firm plans to focus on driving more growth globally. He also revealed that the company wants to divert its attention towards the expansion of category leadership with the aim of deriving a strong financial performance as well as advanced patient care.

“We are committed to fulfilling our promises to patients, customers and shareholders by delivering a comprehensive, innovative and cost-effective portfolio of products and solutions within our served markets while also expanding into new, high-growth adjacent markets,”stated Mahoney.

The company’s products are sold to more than 24 million patients globally, bringing total global revenue to about $40 billion. Boston Scientific wants to push this number to $50 billion in the next three years, which is a very reasonable goal given its upcoming technologies and products. The company’s leaders highlighted the products and technologies during the New York meeting. Some of the segments in which the company plans to focus on leadership include MedSurg, Rhythm Management, and Cardiovascular segments.

Dan Brennan, the chief financial officer and executive vice president of Boston Scientific stated that company’s long term outlook involves diversification into large, high-growth markets that offer more capabilities as well as a wider portfolio. He also revealed that it was in the firm’s interest to widen its presence beyond the U.S., in developed as well as emerging markets. This strategy will be key towards achieving the expected revenue increment by 2020.

Boston Scientific has so far been registering significant and steady growth in its current markets. The company executives are confident that the new plans will help achieve the growth objectives and perhaps even push the firm to new revenue heights. The announcements should also encourage positive growth expectations from its investors.

Boston Scientific stock closed the latest trading session on Wednesday at $27.82 after declining by 1.07% from the previous close.